Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Drop in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 19,300 shares, a decline of 93.8% from the January 15th total of 311,700 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is presently 0.0 days.

Salarius Pharmaceuticals Stock Down 5.5 %

Shares of SLRX traded down $0.10 on Wednesday, hitting $1.71. The company’s stock had a trading volume of 60,845 shares, compared to its average volume of 4,547,321. The firm’s fifty day moving average price is $1.93 and its 200-day moving average price is $1.78. Salarius Pharmaceuticals has a fifty-two week low of $1.22 and a fifty-two week high of $7.20. The firm has a market capitalization of $2.70 million, a price-to-earnings ratio of -0.21 and a beta of 0.84.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.